Organogenesis Holdings Inc.
ORGONasdaq
$2.62
↓ -1.9%Jul 17 close · end-of-day
Price
1Y↓ -41.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$334.8M
Enterprise Value
$243.4M
P/E
—
P/S
0.7
P/B
1.4
EV/EBITDA
13.1
PEG
—
FCF Yield
5.1%
Dividend Yield
—
Revenue (TTM)
$514.7M
Net Income (TTM)
$2.7M
Free Cash Flow (TTM)
$17.1M
Gross Margin
—
Operating Margin
0.5%
Net Margin
0.5%
ROE
1.1%
ROIC
1.1%
Debt / Equity
—
Net Cash
$91.4M
Return 1Y
-39.9%
Company profile
Organogenesis Holdings Inc. develops, manufactures, and commercializes solutions for the advanced wound care, surgical and sports medicine markets in the United States. The company's products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved. NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; NuShield is a wound-covering tissue. NuCel is a dehydrated placental tissue surgically applied to the target tissue to support native healing. Nu
- CEO
- Gary S. Gillheeney
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 950
- Headquarters
- Massachusetts
- Website
- organogenesis.com
Management & directors
- Cavorsi RobertVice President, Strategy
- Bilbo PatrickChief Operating Officer
- Francisco DavidChief Financial Officer
- Freedman LoriChief Admin. and Legal Officer
- Gillheeney Gary S.President and CEO
- Grow BrianChief Commercial Officer
- Montecalvo Antonio S.Vice President, Health Policy
Roles derived from SEC Form 4 filings.
Earnings
ORGO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$37.2M↓ -57.1%
Diluted EPS-$0.44↑ +158.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $338.3M | $467.4M | $450.9M | $433.1M | $482.0M | $564.2M |
| Gross profit | $251.0M | $353.2M | $345.9M | $326.7M | $366.3M | — |
| Operating income | $26.7M | $72.2M | $22.3M | $12.5M | -$1.3M | $44.7M |
| Net income | $17.2M | $94.2M | $15.5M | $4.9M | $900,000.00 | $37.0M |
| Diluted EPS | $0.15 | $0.70 | $0.12 | $0.04 | -$0.01 | $0.15 |
| Operating cash flow | $5.5M | $62.0M | $24.9M | $30.9M | $14.2M | -$10.3M |
| Free cash flow | -$12.2M | $30.8M | -$9.0M | $6.6M | $4.2M | -$24.5M |
| Gross margin | 74.2% | 75.6% | 76.7% | 75.4% | 76.0% | — |
| Operating margin | 7.9% | 15.5% | 4.9% | 2.9% | -0.3% | 7.9% |
| Net margin | 5.1% | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $130.2M | $115.2M | $126.7M | $86.7M | $101.0M | $150.9M | $225.6M | $37.2M |
| Gross profit | $101.0M | $88.4M | $95.6M | $63.0M | — | — | — | — |
| Operating income | -$13.9M | $6.2M | $10.2M | -$26.7M | -$12.6M | $20.7M | $63.3M | -$68.9M |
| Net income | -$17.0M | $12.3M | $7.7M | -$18.8M | -$9.4M | $21.6M | $43.7M | -$53.2M |
| Diluted EPS | -$0.13 | $0.09 | $0.05 | -$0.17 | -$0.10 | $0.11 | $0.31 | -$0.44 |
| Operating cash flow | $4.7M | $8.7M | $10.9M | -$19.9M | -$32.9M | $3.1M | $39.4M | $21.1M |
| Free cash flow | $2.9M | $6.1M | $7.6M | -$23.6M | -$36.5M | $844,000.00 | $34.8M | $18.0M |
| Gross margin | 77.6% | 76.7% | 75.5% | 72.6% | — | — | — | — |
| Operating margin | -10.7% | 5.4% | 8.1% | -30.9% | -12.5% | 13.7% | 28.1% | -185.1% |
| Net margin | -13.1% | 10.7% | 6.1% | -21.7% | -9.3% | 14.3% | 19.4% | -142.8% |
Company news
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-09 | Driscoll Michael Joseph | Buy | 10,000 | $2.67 | $26,688.00 | filing |
| 2026-03-09 | Leibowitz Arthur S | Buy | 5,000 | $2.68 | $13,405.00 | filing |
| 2026-03-01 | Cavorsi Robert· Vice President, Strategy | Tax withholding | 700 | $3.21 | $2,247.00 | filing |
| 2026-02-18 | Gillheeney Gary S.· President and CEO | Tax withholding | 91,311 | $3.84 | $350,634.24 | filing |
| 2026-02-18 | Gillheeney Gary S.· President and CEO | Tax withholding | 90,398 | $3.84 | $347,128.32 | filing |
| 2026-02-18 | Bilbo Patrick· Chief Operating Officer | Tax withholding | 16,375 | $3.84 | $62,880.00 | filing |
| 2026-02-18 | Bilbo Patrick· Chief Operating Officer | Tax withholding | 16,212 | $3.84 | $62,254.08 | filing |
| 2026-02-18 | Francisco David· Chief Financial Officer | Tax withholding | 14,687 | $3.84 | $56,398.08 | filing |
| 2026-02-18 | Francisco David· Chief Financial Officer | Tax withholding | 14,541 | $3.84 | $55,837.44 | filing |
| 2026-02-18 | Freedman Lori· Chief Admin. and Legal Officer | Tax withholding | 14,411 | $3.84 | $55,338.24 | filing |
| 2026-02-18 | Freedman Lori· Chief Admin. and Legal Officer | Tax withholding | 14,267 | $3.84 | $54,785.28 | filing |
| 2026-02-18 | Grow Brian· Chief Commercial Officer | Tax withholding | 11,887 | $3.84 | $45,646.08 | filing |
| 2026-02-18 | Grow Brian· Chief Commercial Officer | Tax withholding | 11,768 | $3.84 | $45,189.12 | filing |
| 2026-02-18 | Cavorsi Robert· Vice President, Strategy | Tax withholding | 5,487 | $3.84 | $21,070.08 | filing |
| 2026-02-18 | Cavorsi Robert· Vice President, Strategy | Tax withholding | 5,432 | $3.84 | $20,858.88 | filing |
| 2026-02-18 | Montecalvo Antonio S.· Vice President, Health Policy | Tax withholding | 3,778 | $3.84 | $14,507.52 | filing |
| 2026-02-18 | Montecalvo Antonio S.· Vice President, Health Policy | Tax withholding | 3,741 | $3.84 | $14,365.44 | filing |
| 2026-02-18 | Bilbo Patrick· Chief Operating Officer | Award | 48,612 | $0.00 | $0.00 | filing |
| 2026-02-18 | Gillheeney Gary S.· President and CEO | Award | 890,625 | $0.00 | $0.00 | filing |
| 2026-02-18 | Gillheeney Gary S.· President and CEO | Award | 186,968 | $0.00 | $0.00 | filing |
| 2026-02-18 | Driscoll Michael Joseph | Award | 48,828 | $0.00 | $0.00 | filing |
| 2026-02-18 | Giacomin Jon L | Award | 48,828 | $0.00 | $0.00 | filing |
| 2026-02-18 | Leibowitz Arthur S | Award | 48,828 | $0.00 | $0.00 | filing |
| 2026-02-18 | Montecalvo Antonio S.· Vice President, Health Policy | Award | 40,625 | $0.00 | $0.00 | filing |
| 2026-02-18 | Montecalvo Antonio S.· Vice President, Health Policy | Award | 11,218 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.